AChE/BuChE-IN-7 is a dual-action inhibitor with an IC50 value of 0.15 μM for acetylcholinesterase (AChE) and 0.7 μM for butyrylcholinesterase (BuChE), with a selectivity index (SI) of 4.7. It exhibits antioxidant activity, reducing H2O2-induced cytotoxicity, and shows genomic stability and extended systemic bioavailability. AChE/BuChE-IN-7 is applicable for research into neurological disorders, such as Alzheimer's disease.

AChE:0.15 μM

AChE/BuChE-IN-7 (Compound D9) demonstrates low cytotoxicity in HT-22 mouse hippocampal neuronal cells at concentrations ranging from 10 to 80 μM, with an IC₅₀ value exceeding 80 μM. At 5 to 20 μM, administered 4 hours before H₂O₂ exposure, it provides significant neuroprotection against oxidative stress injury in HT-22 cells. AChE/BuChE-IN-7 exhibits potent DPPH radical scavenging and ferrous ion chelating activities, with IC₅₀ values of 46.9 μM and 15.7 μM, respectively. It shows moderate DNA binding affinity at 0 to 200 μM and contributes to maintaining genomic stability in HT-22 cells. Additionally, it binds to human serum albumin (HSA) via a static quenching mechanism, thereby extending circulation time at concentrations from 0 to 250 μM. The compound also binds to Alzheimer's disease-related targets with high affinity.